Metabolic/Weight

Liraglutide

Research Reagent · Laboratory Use Only

Quick Answer

What does research show about liraglutide's mechanism of action and metabolic effects?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics endogenous incretin hormones. Research published in Diabetes Care and NEJM demonstrates it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signalling, with cardiovascular outcome benefits observed in the LEADER trial (Marso et al., 2016).

PMID42025665↗DOI10.1016/S0140-6736(09)60663-8↗⟳ Reconstitution Calculator
Scientific AbstractPMID 42025665 · 2026

Purpose

To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from clinical trials. DESIGN: Retrospective, population-based cohort study. PARTICIPANTS: Adults aged ≥18 years with T2D (with hemoglobin A1c of ≥6.5%) and a pre-existing diagnosis of DR from the TriNetX research network database between January 1, 2015, and December 31, 2022.

Methods

The study included 173,216 adults with T2D, all of whom had DR, adjusted for baseline characteristics through propensity score matching (PSM) based on whether the individuals received at least two prescriptions of a GLP-1 RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) at least six months apart. MAIN OUTCOME MEASURES: Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident macrovascular and microvascular complications over a two-year follow-up period.

Results

After PSM, 30,613 individuals (mean [SD] age, 61.6 [11.4] years; 53.2% were females) were prescribed GLP-1 RAs. Patients on GLP-1 RAs had a decreased risk of myocardial infarctions (MIs; hazard ratio [HR], 0.65; 95% CI, 0.61-0.69), coronary artery revascularization procedures (HR, 0.75; 95% CI, 0.67-0.84), heart failure exacerbations (HR, 0.78; 95% CI, 0.76-0.81), ischemic strokes (HR, 0.78; 95% CI, 0.74-0.83), lower extremity amputations (HR, 0.78; 95% CI, 0.69-0.88), acute kidney injuries (AKI; HR, 0.68; 95% CI, 0.66-0.71), or the need for renal replacement therapy (RRT; HR, 0.40; 95% CI, 0.36-0.43). Fewer individuals also progressed to proliferative diabetic retinopathy (HR, 0.78; 95% CI, 0.71-0.86), experienced retinal vein occlusions (RVOs; HR, 0.70; 95% CI, 0.61-0.80), or developed neovascular glaucoma (HR, 0.65; 95% CI, 0.47-0.89); no association was observed for retinal artery occlusions (RAOs; HR, 0.85; 95% CI, 0.57-1.26) or cases of non-arteritic ischemic optic neuropathy (NAION; HR, 0.88; 95% CI, 0.54-1.44).

Conclusions

In patients with T2D and pre-existing DR, the use of GLP-1 RAs was associated with a reduced risk of major macrovascular and microvascular complications, including those directly affecting the retina. Future studies are needed to assess the extent to which GLP-1 RAs benefit long-term outcomes.

Source:10.1016/S0140-6736(09)60663-8
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Liraglutide?

Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) used in type 2 diabetes management. This retrospective cohort study evaluated its association with reduced macrovascular and microvascular complications in patients with concurrent diabetic retinopathy (DR).

Mechanism of Action

Liraglutide functions as a GLP-1 receptor agonist that enhances insulin secretion in response to hyperglycemia, slows gastric emptying, and promotes satiety. The mechanism extends beyond glycemic control to include cardioprotective and renoprotective pathways through activation of GLP-1 signaling cascades, which reduce inflammatory markers and improve endothelial function in both systemic and retinal vasculature.

Observed Laboratory Results

  • Macrovascular Protection: Patients on GLP-1 RAs (including liraglutide) demonstrated a 35% reduction in myocardial infarction risk (HR 0.65; 95% CI, 0.61-0.69) and a 22% reduction in ischemic stroke risk (HR 0.78; 95% CI, 0.74-0.83) over two years.

  • Microvascular and Renal Benefits: Acute kidney injury (AKI) risk decreased by 32% (HR 0.68; 95% CI, 0.66-0.71), while renal replacement therapy (RRT) necessity declined by 60% (HR 0.40; 95% CI, 0.36-0.43).

  • Retinal Outcome Improvements: Progression to proliferative diabetic retinopathy decreased by 22% (HR 0.78; 95% CI, 0.71-0.86), and retinal vein occlusions (RVOs) risk reduced by 30% (HR 0.70; 95% CI, 0.61-0.80) among 30,613 matched participants.

Clinical Research Parameters
10 trials4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Registered Clinical Trials
ClinicalTrials.gov ↗
NCT05767255 ↗
UNKNOWNPhase IIIn=66

Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue

The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule. The DUAL (Dual Action of Liraglutide and Insulin Degludec) studies are the pivotal studies of this combination. Specifically, the DUAL VII study has demonstrated that ideglira i

Study Interventions
insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart
Primary Endpoints
To compare the percentage of hypoglycemia
Study Period
2022-12-01 → 2023-08-30
NCT03235050 ↗
COMPLETEDPhase IIn=834

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

Study Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
Primary Endpoints
Change in HbA1c; Percent Change in Body Weight
Study Period
2017-08-02 → 2019-06-14
NCT02001363 ↗
UNKNOWNN/An=90

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.

Study Interventions
liraglutide (Novo Nordisk, Bagsværd, Denmark), liraglutide placebo (Novo Nordisk)
Primary Endpoints
the salvage index measured by cardiac magnetic resonance
Study Period
2013-11 → 2016-03
NCT02104037 ↗
COMPLETEDN/An=8

Liraglutide in Spinal Fluid

The purpose of this study is to investigate transfer of liraglutide from blood to cerebrospinal fluid.

Study Interventions
Lumbar puncture
Primary Endpoints
cerebrospinal fluid concentration of liraglutide
Study Period
2012-01
NCT02686177 ↗
COMPLETEDPhase IVn=50

Effect of GLP-1 on Angiogenesis

GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications associated with T2D. Few studies have properly addressed the role of GLP-1-based therapies in regulating vascular integrity and angiogenesis. The study evaluate the impact of o

Study Interventions
Liraglutide, Metformin or sulfonylurea
Primary Endpoints
Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group
Study Period
2016-05-18 → 2021-05-28
NCT01299012 ↗
COMPLETEDN/An=30

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

Evaluating the use of Liraglutide in patients with Type 1 Diabetes.

Study Interventions
Liraglutide
Primary Endpoints
Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide
Study Period
2010-10 → 2013-06
NCT02109315 ↗
WITHDRAWNPhase I0

Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function

Study Interventions
Vitamine C, Liraglutide 6 mg
Primary Endpoints
Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.
Study Period
2014-05 → 2015-05
NCT02443155 ↗
COMPLETEDPhase IIn=308

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.

Study Interventions
NNC0114-0006, liraglutide, placebo
Primary Endpoints
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline
Study Period
2015-11-10 → 2019-02-27
NCT01890993 ↗
COMPLETEDN/An=952

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Study Interventions
liraglutide
Primary Endpoints
Change in HbA1c (glycosylated haemoglobin)
Study Period
2013-08 → 2014-06
NCT01722240 ↗
COMPLETEDPhase IIIn=69

Liraglutide in Type 1 Diabetes

The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes. The investigators have, therefore, designed this study to investigate the central hypothesis that in patients with type 1 diabetes, Liraglutide has a glucose lowering effect. A major secondary objective of this st

Study Interventions
Liraglutide 1.8mg, Placebo
Primary Endpoints
HbA1c (%)
Study Period
2012-11-01 → 2019-07-29
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. Liraglutide is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 42025665) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Metabolic/Weight Research Compounds

Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for the management of ob…
→
Tirzepatide
INTRODUCTION: Tirzepatide has been associated with significant reductions in body weight i…
→
Retatrutide
OBJECTIVES: Functional co- and tri-agonists at the receptors for GLP-1, GIP and glucagon e…
→
MOTS-c
OBJECTIVE: MOTS-c is a mitochondria-derived peptide associated with reduced insulin resist…
→
View all Metabolic/Weight compounds →